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Introduction
The disparities of medical practice, together with a grow-
ing number of possible interventions, have increased the
demand for well-conceived guidance for practitioners [1].
However, this development is hampered by the number and
quality of scientific studies that test medical hypotheses,
which are often unsatisfactory. This is especially true in
nephrology, where well-conducted controlled trials are rare
[2]. Because patients with renal failure are generally ex-
cluded from controlled studies in the general population
[3], the development of sufficiently well-founded guidance
in nephrology has always been difficult.
With the development of European Best Practice Guide-
lines (EBPG), the European Renal Association–European
Dialysis and Transplantation Association (ERA–EDTA)
has created its own guidance-generating process. Similar
initiatives have also arisen in the USA (Kidney Disease
Outcome Initiative—K/DOQI), Australia (Caring for
Australasians with Renal Impairment—CARI), Canada
(Canadian Society of Nephrology—CSN), the UK (United
KingdomRenal Association—UKRA), as well as at several
other locations around the world. These institutions have
generated a plethora of often parallel recommendations on
similar topics but sometimes with different messages [4].
The question can be asked: ‘Is there still a place for an
institution generating European nephrology guidance?’ If
there is, how should such an initiative be managed to con-
form with current demands? To answer these questions, the
Council of ERA–EDTA set up a commission that convened
three times in the course of 2008–09.
The present text is a distillation of the discussions, reflec-
tions and final conclusions of this commission. It is an ad
hoc document, reflecting the current status. In the future,
concepts and attitudes might change, as medical thinking
is influenced by changes in practice, needs, general philos-
ophy, ethics and political/financial conditions.
Potential future of European nephrology guidance
The nephrology guidance landscape was thoroughly mod-
ified with the advent of the Kidney Diseases Improv-
ing Global Outcome (KDIGO) initiative, a body that
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Table 1. Documents generated up till now by the European Best Practice
Guidelines (EBPG)
Topic Year
EBPG
Anaemia 1999
Transplantation (pre-transplantation) 2000
Ca/P algorithma 2001
Haemodialysis (first wave) 2002
Transplantation (post-transplantation) 2002
Anaemia (update) 2004
Peritoneal dialysis 2005
Haemodialysis (second wave) 2007
ERBP
Anaemiab 2008
Hepatitis Cb 2008
aNo real ‘guidelines’ but series of algorithms, generated by European
experts, not under the responsibility of ERA–EDTA.
bPosition statement.
establishes global nephrology guidelines on a worldwide
basis [5]. However, the number of topics and necessary
updates is too large to be dealt with by KDIGO alone.
KDIGO have therefore installed a coordination task force
having representation from all other major guidance initia-
tives. It was originally thought that KDIGO would cover
the whole spectrum, producing new and updated nephrol-
ogy guidelines on any theme considered suitable. In 2006,
the KDIGO Board of Directors decided to concentrate on
selected topics only. This opened up a new opportunity
for existing guidance bodies, both European and other, to
take a more active role in the formulation of nephrology
recommendations.
History of European nephrology guidance
initiatives
The ERA–EDTA has produced nephrology guidance doc-
uments since 1999 on the treatment of renal anaemia;
haemodialysis; peritoneal dialysis and transplantation (Ta-
ble 1) [6]. Clinical nephrology recommendations have not
yet been generated. Whereas guidance produced by other
bodies (e.g. K/DOQI) has often been restrictive and fo-
cused on specific themes, the design of European guid-
ance, in general, has been more comprehensive, at the
expense of taking a position in areas where the evidence
was weak. EBPG produced only one update, in 2004, on
anaemia. EBPG has also collaborated with K/DOQI on
bone metabolism; hypertension in CKD; cardiovascular
disease in dialysis and anaemia (2006 update) and with
KDIGO on hepatitis C [7]. Also to be noted is that K/DOQI
invited several European experts who, in the final drafts,
were referred to as ‘liaison’ members to the work groups.
Several European experts are collaborating with KDIGOon
the upcoming guidelines on bone and mineral metabolism
and on the care of the kidney transplant recipients.
Outline of further action
Before starting a specific action, a think tank of 20 Euro-
pean experts in guidance development was appointed by
the ERA–EDTA Council to develop over a ±1-year pe-
riod a further plan for the future. The group was mainly
composed of the physicians who are the most affected by
these documents, i.e. nephrologists, including a paediatric
nephrologist and renal epidemiologists. Several members
had previously participated in the development of EBPG on
anaemia, haemodialysis, peritoneal dialysis or transplanta-
tion; some of the participants had also been involved in the
development of K/DOQI and KDIGO guidelines (Table 2),
whilst others serve on the ERA–EDTA Council. During
the course of its activity, the group was extended by sev-
eral non-nephrologists, i.e. a clinical scientist, a renal nurse
and a patient who also worked for 33 years as a general
practitioner (Table 2).
Although a further extension of the group by non-
nephrologists (e.g. by an ethicist) was considered, this was
eventually deemed unnecessary at the current time. If there
is a need, ad hoc advicewill be sought from specific experts.
The group mentioned above will serve as Advisory
Board, meeting on a regular basis several times a year to
consider potential topics, the need for updates and adapta-
tions to existing documents and their implementation. This
Advisory Board should take decisions about further action
based on existing and new evidence. This Board should
appoint extended scientific area work groups (involving
experts in a specific field) (see the ‘Composition of work
group’ section).Members of this Advisory Board should be
selected by the Council of ERA–EDTA based on their spe-
cific competences and CVs. The Board composition should
be based on an alternating rotation system after a pre-set
number of years, which should be specified in the Board’s
bylaws.
The Board should also appoint specific watchdogs (see
the ‘Literature watch’ section), who could be defined as
area experts to advise the Board about new relevant data in
specific fields and the need to, or possibility of, generate
new recommendations.
A change in scope and philosophy
At the very beginning of the discussions of the Advisory
Board, the lack of knowledge and evidence due to a shortage
of randomized controlled trials (RCTs) was acknowledged
[6]. Such uncertainty creates a problem for the production
of new ‘guidelines’ and necessitates a search for clear def-
initions and alternative formats, to avoid confusing those
who may otherwise consider the statements as too strong
if they are based on rather weak evidence. Offering guid-
ance should be done with sufficient transparency such that
deficits, due to lack of evidence, are acknowledged.
On the other hand, the need to offer guidance in areas
where there is not much evidence is also recognized. ERA–
EDTA has a responsibility to offer guidance from experts
to clinicians especially in those areas. The latter category
of guidance can be offered in a format that differs from
traditional ‘guidelines’. The Advisory Board decided that
the best way for this to be done was to implement ‘rec-
ommendations’ and ‘position statements’ in new formats
summarizing the state of the art for a specific topic, where
the available evidence and/or expertise are translated into a
broad European perspective. To emphasize this change in
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Table 2. Members of the ERBP Advisory Board, together with their expertise, experience with other guideline bodies and nationalities
KDIGO K/DOQI EBPG Other Expertise Country
Abramovicz Daniel X TP Belgium
Cannata Jorge X X Gen Spain
Cochat Pierre X Paediatrician Gen/TP France
Covic Adriana X East Europe HD Rumania
Eckardt Kai-Uwe X X X Anaemia Germany
Fouque Denis X X X Gen France
Heimburger Olof X PD Sweden
Jenkins Simon Patient UK
Lindley Elizabeth X Clinical scientist Gen/HD UK
Locatelli Francesco X X X Gen/Anaemia Italy
London Ge´rardb Gen/HD France
MacLeod Alison X X X Guideline methodologist Gen UK
Marti Anna Renal nurse HD Spain
Spasovski Goce Eastern Europe Gen/HD FYROM
Tattersall James X X HD UK
Van Biesen W PD Belgium
Vanholder R X X X HD Belgium
Wanner Christoph X X X HD Germany
Wiecek Andrej X X Eastern Europe Gen/HD Poland
Zoccali Carmine X X Gen Italy
TP: transplantation; Gen: general nephrology; PD: peritoneal dialysis; HD: haemodialysis.
aEx officio as Secretary Treasurer of ERA–EDTA.
bEx officio as President of ERA–EDTA.
scope, it was decided to modify the name from EBPG to
ERBP (European Renal Best Practice) [6].
The structure is functioning under the ERA–EDTA, with
an Advisory Board (see the ‘Outline of further action’ sec-
tion) that serves as one of the Advisory Boards of ERA–
EDTA. The Advisory Board decides the topics on which
statements should be made, the format (i.e. recommenda-
tion, guideline, position statement or other) appointments
the chairmen of the work groups that are going to address
a particular topic, and reviews the final draft before its
submission. In addition, the Advisory Board is in contact
with other guidance bodies such as KDIGO to facilitate the
harmonization of initiatives, and also, via the liaison task
force of KDIGO, with K/DOQI, CARI, CSN and UKRA
(Figure 1).
Definitions
There has been extensive discussion within both the ERBP
Advisory Board and the KDIGO Executive Committee and
Board of Directors about the terminology used in guidance
documents and themethodology used to grade the quality of
evidence and strength of recommendations. Tables 3 and 4
summarize the definitions and interpretations as they stood
in January 2009. Worldwide the methodology is evolving,
so it is possible that there will be further adaptations.
Quality of evidence
Evidence should be graded according to the GRADE sys-
tem [8]. KDIGO have decided to use A, B, C and D to
describe the four grades of evidence quality, based on a
GRADE document published in 2008 (Table 3) [9].
The following parameters should be considered: (1) the
quality of evidence; (2) the balance of health benefits and
harms; and (3) the balance of net financial benefits and
Table 3. Grading of quality of evidence
KDIGO grade GRADE grade
for quality of for quality of
evidence evidence Meaning
A High We are confident that the true
effect lies close to our estimate
of the effect
B Moderate The true effect is likely to be
close to our estimate of the
effect, but there is a possibility
that it is substantially different
C Low The true effect may be
substantially different from our
estimate of the effect
D Very low Our estimate of the effect is just a
guess, and it is very likely that
the true effect is substantially
different from our estimate of
the effect
costs; the latter element becomes increasingly important as
resources become more and more limited.
Strength of guidance statements
The strength of a guidance statement indicates the extent
to which one can be confident that adherence to the rec-
ommendation will do more good than harm. The level of
confidence depends not only on the quality of the evidence
but also on the judgment of the experts in the work group
[9]. Only two statement strengths have been defined by
KDIGO (Table 4), with Level 1 referring to ‘strong’ rec-
ommendations.
When judgment is brought in, high-quality evidence does
not always lead to Level 1 guidance statements and vice
versa. In situations where there is high-quality evidence
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ERA-EDTA
ADVISORY BOARD
ERBP
OTHER
ADVISORY BOARDS
WORK GROUPS
ON SPECIFIC TOPICS
SUBGROUPS
ON SUBTOPICS
KDIGO
LIAISON
TASK
FORCE
CSN
CARI
KDOQI
UKRA
Fig. 1. Structure of ERBP and its Advisory Board, and their relation to ERA–EDTA and other guidance generating bodies.
Table 4. Grading of strength of recommendation
Implications
KDIGO grade Patients Clinicians Policy
Level 1 ‘We
recommend. . .’
Most people in the situation will
want the recommended course of
action and only a few will not
Most patients should receive the
recommended course of action
The recommendation could be
adopted as a policy
Level 2 ‘We
suggest. . .’
The majority of people in the
situation would want the
recommended course of action, but
a substantial minority would not
Different choices will be appropriate
for different patients. Patients will
need help to arrive at a
management decision consistent
with their values and preferences
There is a need for substantial debate
and involvement of stakeholders
that an intervention would be effective, but the interven-
tion has frequent and/or serious side effects, the strength
of the guidance statement may be moved to Level 2
(‘weak’).
Lower quality evidence, based on good clinical practice
or widespread experience that is unlikely to be tested by an
RCT, could lead to a Level 1 guidance statement if the work
group members judge the intervention to be beneficial, and
if the risk involved is low enough to allow the intervention
to be used unconditionally in most cases (e.g. the use of
dialysis to treat end-stage or acute renal failure; the use of
anticoagulants in haemodialysis).
When the strength of the guidance statement and the
evidence quality are combined, there are eight grades (1A
to 2D). KDIGO are intending to use this system based on
symbols, rather than words. The ERBPAdvisory Board felt
that the guidance statements should give both the overall
grade and an explanation of the grade for each statement
in words. For example: ‘Grade 2D (weak recommendation;
low-quality evidence)’.
Within the KDIGO system, it is also possible to make an
‘ungraded’ statement. The wording for these statements is
likely to be ‘It would be reasonable to. . .’ rather than ‘We
recommend/suggest. . .’. ERBP accepts this ninth grade as
well. To avoid confusion, it is, however, recommended to
only use this kind of statement exceptionally.
To emphasize the difference between graded and un-
graded statements, the former should be boxed, but with
Level 1 statements in bold, and ungraded statements should
be unboxed bullet points.
Guidance documents
Currently, KDIGO are using the word ‘guideline’ to refer
to the document (the ‘book’) containing all statements, re-
gardless of the overall grade. Where insufficient evidence
is available, the ERBP Advisory Board prefers to refer to
the document as ‘best practice recommendation’ rather than
‘best practice guideline’ unless all statements contained are
of Level 1.
Both KDIGO and the ERBP Advisory board are using
a ‘position statement’ to describe a document that relates
to best practice but is not based on a systematic litera-
ture review and a stringent process of synthesis, evaluation
and external review by the group producing the document.
Examples of ERBP position statements are the commen-
tary on renal anaemia and the endorsement of the KDIGO
guideline on hepatitis [10,11].
Direct activities
Adaptations of existing ‘guidelines’
The existing ‘guidelines’ should be adapted to match major
new evidence. This not only implies the updating of current
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guidance texts but also the development of a strategy to
screen for evidence that is important enough to justify ad
hoc changes (see the ‘Literature watch’ section—watchdog
function). Recent examples of guidance documents that
might need modification are the target haemoglobin levels
for renal anaemia treatment where published evidence [12–
14] was the subject of a specific ERBP position statement
[10] and the example of biocompatibility and dialyser flux
in haemodialysis, which might need reformulation after
the results of the MPO study have been published [15].
For keeping existing guidance texts up to date, the most
convenient option is to delegate this task to the group or
members of the Advisory Board who have been responsi-
ble for the corresponding previous guideline, at the behest
of the ERA–EDTA Council. If considered necessary, they
should work in conjunction with experts in the field who
are not Board members.
The ERBP Board’s priority must be to update existing
‘guidelines’ rather than create new recommendations, since
maintaining outdated ‘ghost guidelines’ is not desirable.
Potential candidates for updating in the near future are
as follows:
Transplantation. Transplantation recommendations were
published by EBPG in 2000 and 2002 [16,17]. Since that
time, much new evidence in this area has been generated.
It has been taken into account that KDIGO is currently
drafting transplantation guidelines. ERBP plans to write
a position statement on the KDIGO document when it is
published and to focus its recommendations on topics that
will not be included by KDIGO, such as pre-transplantation
work-up, both of donor and recipient; living donation; ex-
tended, non-heart beating donors; and pre-emptive trans-
plantation. The American Transplantation Society (AST)
should also be contacted to avoid overlap.
Haemodialysis. Haemodialysis recommendations were
published by ERBP in 2002 and 2007 [18–22]. Especially
the first wave might require updating, but probably only on
selected topics such as dialysis water quality. Reformula-
tion of other topicsmight be needed once newRCTs appear,
such as the MPO study [15] for the adequacy of dialysis;
the AURORA study and the SHARP study [23] for cardio-
vascular disease; or the IDEAL study [24] for the start of
dialysis.
The topic on the ‘start of dialysis’ might be extended to
cover the process of delivering care to patients with CKD
stages 3 and 4, including the choices of available dialysis
modalities, ethical considerations and the approach to older
patients (see the ‘Coverage of new topics’ section).
Anticoagulation. Until now, EBPG has been focusing
only on anticoagulation during haemodialysis [18]. How-
ever, also anticoagulation of dialysis patients for other rea-
sons (e.g. in relation to cardio-vascular disease or to main-
tain vascular access function), anticoagulation in the earlier
stages of CKD and central vein catheter locks might be
taken into consideration.
Peritoneal dialysis. PD recommendations were published
by EBPG in 2005 [25]. There is not much evidence in this
area. In keeping with the section above entitled ‘A change
in scope and philosophy’, it is thought that the previous
‘guidelines’ would better be replaced by a position state-
ment that refers to the 2005 documents.
Literature watch
In view of the definition of evidence quality and recom-
mendation strength, a ‘literature watch service’ (watch-
dogs) for different topics has been established. Topics will
be distributed among Advisory Board members. They will
perform an ongoing screen for studies that ‘are likely to
change the view/attitude towards a certain problem’ and
that might engender a reason to adapt/update recommen-
dations or generate position statements. The results of such
screening activity will be posted through the Nephrol Dial
Transplant-Educational literature survey.
Coverage of new topics
A second potential task is to start covering topics that
have never been dealt with by European guidance bod-
ies. This is especially true for clinical nephrology topics
that fall outside the area of renal replacement therapy, e.g.
IgA nephropathy, nephrotic syndrome, etc. But the deci-
sion about which topics to address should be made by the
Council, advised by the Advisory Board. The decision to
cover a given topic should be made after reviewing existing
guidance documents from other bodies (CARI, UK, CNS,
K/DOQI) to avoid overlap, and through the use of harmo-
nization with those organizations to prevent parallel efforts.
The coordination and liaison initiative from KDIGO [26]
might be the correct forum to facilitate decisions in this
regard.
However, updating the existing ‘guidelines’ generated in
the past remains the priority. New ‘guidelines’ or recom-
mendations should only be considered if the allotted budget
allows room for new incentives.
Composition of work groups
The structure generating the documents containing the
statements should consist of a number of work groups.
Each work group, with a maximum membership of 16,
should have a chair and vice-chair, chosen because of their
personal expertise and publications. These chairswill act in-
dependently in composing their groups. If a work group has
several subgroups, the subgroup chairs should be appointed
by the main work group (Figure 1). Themembership should
preferably include non-nephrologists. Members might also
be sought from outside Europe.
Recommendations on off-label therapies/drugs
Compared to other geographical areas such as the USA,
the situation for Europe might be difficult since regula-
tions, funding sources and distribution processes can differ
markedly from country to country. If there are differences
in approach between countries, it is often a sign of lack of
evidence. Any such differences should be mentioned in the
comments.
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Relationship with KDIGO and other bodies
From the very beginning, ERA–EDTA endorsed the
KDIGO project to produce global guidelines. KDIGO’s
philosophy is to globalize the evidence and localize the im-
plementation. Many of the members of the Advisory Board
of ERBP also play an active role in KDIGO. The collab-
oration with KDIGO should continue without neglecting
our own European identity. It should be noted that since
the KDIGO project came into effect, duplication no longer
occurs.
KDIGO’s role is concerned more with the coordination
and generation of traditional guidelines and less in issuing
position statements. Here lies a niche for ERBP.
Guidelines generated byKDIGO and other bodies should
be considered by ERBP and endorsed if acceptable. Com-
ments, amendments or caveats that relate to local (Euro-
pean) conditions may if needed be added. Ad hoc commis-
sions will be appointed to produce position statements, to
be published in the core journal of ERA–EDTA, Nephrol
Dial Transplant.
Furthermore, the task of implementation is difficult for
KDIGO to achieve and opens possibilities for local guid-
ance bodies.
Other examples of the interaction between KDIGO and
ERBP currently include mutual links at the respective web-
sites and the liaison task force (see the ‘Coverage of new
topics’ section).
Apart from KDIGO, many other bodies are active in
the generation of guidance. Those initiatives may be re-
viewed by ERBP members, without ERBP formally en-
dorsing them. Other initiatives may be endorsed by ERBP
or published under joint responsibility with ERBP. The Ad-
visory Board will decide the direction to be followed taking
into account the level of evidence, the impact on the nephro-
logical community and patients and the available resources.
Conceptual changes
EBPG have always been developed based on a great deal
of voluntary effort. The number of experts involved has
been low, the support structures weak and the work load
enormous. The following modifications are introduced.
Literature search
Literature search and evidence rating should be offered by
an external professional resource, e.g. the Cochrane group.
The literature search should be constructed on specific
questions based on the PICODD system [27] (Table 5).
The search should be performed in an organized, objec-
tive manner. A specific, predefined procedure should be
adhered to, avoiding any bias. A restriction according to
the impact factor and/or a limitation to only RCTs might be
considered. The algorithm should be traceable.
Meta-analyses
Meta-analyses are a difficult tool for evidence assessment
and may themselves be prone to bias [28]. They are only
Table 5. PICODD system for the literature search
Abbreviation Topic of questions
P Population
I Intervention
C Comparison
O Outcomes
D Design of study (e.g. RCTs)
D Duration of follow-up
RCTs: randomized controlled trials.
considered useful as part of a systematic review including
interpretation and quality assessment of the publications
under consideration. They should only be used to provide
an answer to questions that cannot be solved otherwise,
are strongly dependent upon the quality of the studies in-
cluded and may be only ‘the best available’ evidence until
a definitive large study is done [28].
Peer review
The following groups could be considered to perform peer
review (list non-exhaustive):
Public (interested individuals). The pre-final draft can be
made available for the peer review to the public, especially
for guidance documents of a more extended format than
position statements. This will mean that the draft will be
sent to all members of ERA–EDTA.
Interested societies. It could also be made available to po-
tentially interested societies or other guidance bodies (e.g.
EuropeanDialysis and TransplantationNurses Association/
European Renal Nurses Association—EDTNA/ERNA,
KDIGO, K/DOQI, . . .).
Experts. These should be selected experts, partly non-
European and non-nephrologists.
ERA–EDTA appointed reviewers. Both the members of
the ERBP Advisory Board and the members of the ERA–
EDTA Council, as far as they were not involved in the
development of the document under consideration, may
take part in this process.
The members of the ERBPAdvisory Board who produce
the text should be able to identify the relevant interested so-
cieties and many of the relevant experts. A literature search
should pick up authors not known to the working group.
The system currently used by http://mc.
manuscriptcentral.com for the review of submitted papers
might be adapted for the purpose of reviewing and
commenting on the draft. This would allow reviewers to be
tracked and prompted for comments.
There is a tendency for reviewers not to feed back if
they are happy with the contents, but it is impossible to
perceivewhether the lack of response is due to acceptance or
failure to read the document. Ideally, ERBP should develop
specific tools to define, with minimal effort to the reviewer:
• Which sections were taken into consideration by the
reviewer?
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• How strongly he/she agreed or disagreed with each rec-
ommendation?
• What were his/her reasons for disagreement?
• What was his/her impression of the quality and com-
pleteness of the rationale?
Implementation
Any implementation strategy should have an impact at three
levels: (1) increasing knowledge, (2) changing attitudes
and (3) changing outcomes by improving patient health
and quality of care. There are several obstacles that impede
proper implementation.Many physicians feel that best prac-
tice ‘guidelines’ represent an erosion of clinical freedom.
On the other hand, in specific countries and in specific
units within countries, local circumstances related to eco-
nomic conditions, organization of health care delivery or
even legal, political or cultural constraints might render the
implementation difficult.
Guidance documents are not always sufficiently dissem-
inated down to the level of local users. Their formulation
is often too theoretical and too academic, and especially
at the level of primary care there may be doubts of the
applicability of research findings. Implementation should
be followed up by quality management programmes. Once
an implementation process is applied, it should be contin-
uously monitored and evaluated. Clinical audit and local
service evaluation are quality enhancement processes that
seek to improve patient care and outcomes through the sys-
tematic review of care against explicit criteria; the final aim
is the implementation of change.
Feedback should be obtained on what works, what is
difficult (including the economic effects) and what is coun-
terproductive.
Hence, the question is how to implement implementation.
For this to come to pass, several specific tools are available.
Presentation at ERA–EDTA meetings and other
conventions
ERA–EDTA has a long-standing experience with the pre-
sentation of its guidance documents at its own generalmeet-
ings. From now on, each upcoming ERA–EDTA meeting
will strive to contain at least one session on recent advances
with ERBP. In addition to the specific content of guidance
documents, the following messages should be conveyed:
(1) the important distinction between the strength of evi-
dence levels and their impact on the format of guidance
delivery and (2) the present status of guidance develop-
ment and publication, to avoid the confusion the general
nephrologist faces with a profusion of documents on the
same topics (KDIGO, ERBP, K/DOQI, CARI, etc.).
Additional initiatives should be considered in the follow-
ing fields: presentation of ERBPdocuments at other general
meetings [e.g. American Society of Nephrology (ASN);
European Society for Organ Transplantation (ESOT)], at
specific meetings; at small interactive ERA–EDTA CME
programmes, recommended as one of the most effective
tools as this results in dissemination at local level. Such
sessions could be organized in conjunction with Nephrol-
ogy Society meetings, with simultaneous video transmis-
sion to up to 20 other locations. Two such meetings might
be considered each year. A first initiative will be taken after
the publication of the ERBP position statement [11] on the
KDIGO hepatitis guidelines [7].
Publications and availability on websites
ERA–EDTA has an established ability for extensive pub-
lication of guidance documents (Nephrology Dialysis
Transplantation—NDT) and making them accessible on
websites (http://www.oxfordjournals.org/our_journals/ndt/
era_edta.html). All these aspects should be maintained, and
several practical steps should be taken to further improve
electronic access:
• To present the ERBP position statements.
• To add a link to the KDIGOwebsite in the section ‘other
guidelines’. The KDIGO website (http://kdigo.org/)
contains a comprehensive overview of all major guide-
lines/recommendations and compares guidance state-
ments worldwide about major nephrology issues.
• To add a search engine that would operate on the docu-
ments posted on the website.
Accessing guidance documents via internet will likely be-
come the norm. On-line access has many advantages in-
cluding the following:
• easy searching,
• links to references (PubMed abstract or full text publi-
cations),
• links to glossary of terms (e.g. strong, weak. . .) and
• option to use colour and pop-ups.
CD-ROMs, email blasts
Once the first three ERBP position statements have been
published (one on the name change [6]; one on hepatitis C
[11] and one on anaemia [10]), CD-ROMS and/or e-mail
blasts can be sent out containing these texts separately or
together.
Quiz
Similar to the initiatives previously taken after the publi-
cation of EBPG ‘guidelines’, quizzes allotting CME points
will be published in NDT-Educational. The KDIGO hep-
atitis C guidelines and the ERBP hepatitis C statement will
be the first incentives to generate such a quiz.
Audit
The next implementation step is to audit the application of
the recommendations, either at national or at supranational
level (EDTA registry and others).
This auditing step might include a feedback system, ei-
ther neutral (simple statement), rewarding (bonus) or puni-
tive.
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The QUEST initiative offers a useful tool to perform
active and prospective studies about implementation and
feasibility [29–32].
One should consider the organizations to be contacted
to achieve these aims. Several possibilities are available:
professional bodies; specialty representative groups; scien-
tific/clinical associations; peer review committees; funding
bodies; CME groups; public stakeholders; bodies repre-
sentative for education of patients and allied health pro-
fessionals. A choice and an order of preference should be
made. A structured approach for acting with the help of
national societies and offering them several options should
be considered. Education of the allied health professions
has always been a weak point of ERA–EDTA.
In addition to tackling the scepticism of practicing
nephrologists, one should consider asking national soci-
eties to formally endorse ERBP documents.
Translation into other languages than English
ERA–EDTAwill endorse only its own guidance documents
in the original English version. However, translations are
considered essential tools of external dissemination. Trans-
lation is not a simple task. Misunderstandings are an ever-
present danger.
Translations by national societies will be allowed with-
out requiring a fee. The national societies must obtain per-
mission to make the translation from the ERA–EDTA and
the Oxford University Press. The responsibility for the
translations will be entirely that of the national societies
concerned. No objections will be raised if adaptations or
amendments are introduced, depending on the local condi-
tions and needs. There will be no linguistic double check
of contents. All published ERBP texts (also position state-
ments) should contain the disclaimer: ‘This is the only of-
ficial version endorsed by ERA–EDTA. Any translation or
other adaptation is the responsibility of the body issuing the
new text.’
If the translation is requested by industry, approval should
be given by the ERA–EDTACouncil and the publisher, with
reference to the financial aspect as well. A linguistic double
check is compulsory in those cases.
Abbreviated versions
Abbreviated versions typically contain only the recommen-
dations and might be published separately (e.g. as a pub-
lication in Nephrol Dial Transplant), with the full-length
version in a supplement of Nephrol Dial Transplant Plus.
Abbreviated versions may also be distributed separately,
e.g. as booklets. Abbreviated versions will not be gener-
ated for existing previous EBPG, but only for future ERBP
texts that are yet to be developed.
Financial support
Financial support will be offered by ERA–EDTA in the
context of its educational and research activities.
Supportive structures
One should consider creating a structure that offers specific
professional support. This might include the following:
(1) Board of directors (ERBP Advisory Board members)
chaired by the Advisory Board coordinator.
(2) Development staff
• Nomination of a non-medical manager (main du-
ties: contact person for ERBP Advisory Board;
fund raising).
• Specific secretarial support structure (financial
manager; secretary).
(3) Communication division: The involvement of PR pro-
fessionals is strongly recommended in order to im-
prove dissemination. Communication strategies gen-
erating official press releases, involving medical and
non-medical media, should be developed.
• Communication strategies: After the development
of the ‘guidelines’, the next step is the marketing
effort, both internal and external. Marketing ef-
forts need to be ongoing, repetitive and via different
media.
(a) Internal marketing. Internal marketing is mainly
focused on hitting the targeted stakeholder groups
through the production of flyers, the organiza-
tion of dedicated sessions at scientific meetings
(see the ‘Presentation at ERA–EDTAmeetings and
other conventions’ section) and regular newsletters.
Particular ERA–EDTA newsletters to subscribers
(members and non-members) should provide a tu-
torial link that might guide the users through a se-
ries of informative demonstrations and scenarios
on how to consult clinical practice guidance and
related documents.
(b) External marketing. The following multimedia
tools are considered: newspaper articles, meetings
with health forums, press conferences or one-to-
one interviews (during annual ERA–EDTA meet-
ings), press releases to be sent to European and non-
European journalists, to influential newspapers and
news agencies (i.e. Reuters, DPA) and establishing
a virtual ‘press room’ (making information avail-
able online). Press releases should provide a concise
document that summarizes recommendations for
clinicians (Quick Reference Guide) including the
reasons why the document was developed/needed
as well as person-to-person organization allowing
contact for additional information.
(c) ‘Linkage’—an example of internal and external
marketing: Every document produced by ERBP
should be branded with the ERBP logo (Figure 2).
The logo immediately gives recognition to ERBP
projects and favours the liaison with other interna-
tional guidance groups.
The ERBP webpage with its specific logo should of-
fer an interactive summary of clinical practice guidance
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Fig. 2. ERBP logo.
on nephrology that might potentially help the comparison
among current recommendations for all users.
Conclusions
In the present text, an overview is given on how the activities
of European Renal Best Practice (ERBP), which replaces
the previous European Best Practice Guidelines (EBPG),
are planned to be developed in future years. The main fo-
cus will be on the distinction, in format, between guid-
ance/recommendations/and position statements that are not
well evidenced and guidelines, which are.
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